Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary …
Tag:
Pharmaceuticals
-
-
Lung Transplantation
TFF Pharmaceuticals Announces Interim Data from a Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) to Prevent Lung Transplant Rejection at the 44th International Society for Heart and Lung Transplantation (ISHLT) 2024 Annual Meeting
TFF Pharma Co., Ltd. Oral Presentation Presenting Latest Data from a Phase 2 Study Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC FORT WORTH, Texas, March 25, …
-
News
Eledon Pharmaceuticals Announces Enrollment of 12th Participant in Phase 2 BESTOW Study Evaluating Tegopulvert for Prevention of Organ Rejection
Eredon Pharmaceuticals Co., Ltd. IRVINE, Calif., March 25, 2024 (Globe Newswire) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the registration of 12 pharmaceutical companies.th On March 23, 2024, …
-
Bone marrow transplantion
Tonix Pharmaceuticals completes Phase 1 clinical trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody) in healthy volunteers
Tonix Pharmaceuticals Holding Co., Ltd. Top-line results are expected in the third quarter of 2024.Planning phase 2 trial to prevent kidney transplant rejection Anti-CD40L has multiple potential indications in addition …